SCHEMBL4866244

SCHEMBL4866244

OCCNc1nc(Cc2ccccc2)nc2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.59
POLB P06746 2/20 0.57
TAAR1 Q96RJ0 2/20 0.57
HTT P42858 2/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
ACHE P22303 3/20 0.55
BCHE P06276 2/20 0.55
KDM4E B2RXH2 4/20 0.54
ALDH1A1 P00352 3/20 0.54
RAD52 P43351 3/20 0.54
LMNA P02545 2/20 0.54
GAA P10253 2/20 0.54
MITF O75030 1/20 0.54
TTR P02766 1/20 0.54
GLA P06280 1/20 0.54
RAB9A P51151 1/20 0.54
GBA1 P04062 1/20 0.53
ALOX15 P16050 1/20 0.53
MAPT P10636 2/20 0.52
HPGD P15428 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4859337 0.88 ACHE (0.50) MAPK1POLBTAAR1HTTSMN1; SMN2
SCHEMBL4864862 0.87 APP (0.68) MAPK1HTTACHEBCHEKDM4E
SCHEMBL4859938 0.83 RAD52 (0.69) MAPK1HTTSMN1; SMN2ACHEBCHE
SCHEMBL4863010 0.83 GBA1 (0.58) MAPK1HTTACHEBCHEKDM4E
SCHEMBL16404321 0.80 MAPK1 (0.82) MAPK1POLBTAAR1HTTSMN1; SMN2
SCHEMBL23748460 0.79 RAD52 (0.77) POLBTAAR1HTTSMN1; SMN2ACHE
SCHEMBL4857481 0.78 LMNA (0.64) MAPK1HTTACHEBCHEKDM4E
SCHEMBL23747984 0.77 APP (0.76) POLBTAAR1HTTSMN1; SMN2ACHE
SCHEMBL4859263 0.77 MAPK1 (0.64) MAPK1POLBTAAR1HTTSMN1; SMN2
SCHEMBL7337304 0.77 APP (0.70) MAPK1POLBTAAR1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R MAPK1 513/4885POLB 4499/4885TAAR1 3444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.